SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-027303
Filing Date
2023-08-03
Accepted
2023-08-03 16:41:28
Documents
14
Period of Report
2023-08-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20230802.htm   iXBRL 8-K 40765
2 EX-99.1 a991xforpressreleaseaug320.htm EX-99.1 13595
6 image_0.jpg GRAPHIC 13950
  Complete submission text file 0001628280-23-027303.txt   214348

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20230802.xsd EX-101.SCH 1904
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20230802_lab.xml EX-101.LAB 25850
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20230802_pre.xml EX-101.PRE 13583
8 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20230802_htm.xml XML 2824
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 231140829
SIC: 2836 Biological Products, (No Diagnostic Substances)